Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , July 12, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share.  All of the shares are being sold by Arena.  The gross proceeds
View HTML
Toggle Summary Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , July 11, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering.  Arena expects to grant the underwriters
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension
- Primary efficacy analysis successful - significant improvement in pulmonary vascular resistance<br>- Safety data consistent with other drugs acting through the prostacyclin receptor-mediated effects<br>- Management to host conference call and webcast today at 4:30 p.m. EDT
View HTML
Toggle Summary Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers
SAN DIEGO , June 29, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the completion of a Phase 1 comparative bioavailability study evaluating the pharmacokinetic (PK) profile of extended release (XR) ralinepag compared to the immediate release (IR) formulation in
View HTML
Toggle Summary Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference
SAN DIEGO , June 15, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 21 , at 1:30 p.m. EDT .
View HTML
Toggle Summary Arena Pharmaceuticals Announces Shareholders and Board of Directors Approve Reverse Stock Split
SAN DIEGO , June 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that at the annual meeting of stockholders, held June 13, 2017 , stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company's certificate
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
SAN DIEGO , June 14, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors.  Ms. Jarrett has over 20 years of experience as a senior executive and finance professional in the life sciences industry. 
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th
SAN DIEGO , June 1, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:30am EDT . The conference will take place June
View HTML
Toggle Summary Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
- Lewis Rubin, M.D. and Vallerie McLaughlin, M.D. to Present
View HTML
Toggle Summary Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
SAN DIEGO , May 16, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH),
View HTML